Castle Biosciences (NASDAQ:CSTL) Insider Sells $29,417.83 in Stock

Key Points

• Castle Biosciences insider Derek Maetzold sold 1,339 shares for a total of $29,417.83, decreasing his ownership by 2.00%, leaving him with 65,666 shares valued at $1.44 million.
• The company's stock saw a 4.0% increase in value, reaching $24.41, with a market capitalization of $708.09 million and a current P/E ratio of -69.74.
• Castle Biosciences reported a 15 cent EPS for the recent quarter, significantly beating analysts' estimates of a loss, and expects to post 0.44 earnings per share for the current fiscal year.

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,339 shares of the firm's stock in a transaction dated Wednesday, September 17th. The shares were sold at an average price of $21.97, for a total transaction of $29,417.83. Following the completion of the sale, the insider owned 65,666 shares of the company's stock, valued at $1,442,682.02. This trade represents a 2.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Castle Biosciences Trading Down 1.4%

CSTL traded down $0.33 during trading on Monday, hitting $24.08. The company's stock had a trading volume of 301,635 shares, compared to its average volume of 446,854. The firm's 50 day moving average price is $20.17 and its 200-day moving average price is $19.37. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $35.84. The stock has a market cap of $698.56 million, a PE ratio of -68.80 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.66. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%.The company had revenue of $86.18 million for the quarter, compared to analysts' expectations of $71.53 million. Castle Biosciences has set its FY 2025 guidance at EPS. On average, analysts expect that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CSTL shares. Wall Street Zen raised Castle Biosciences from a "sell" rating to a "hold" rating in a report on Sunday, August 10th. Zacks Research upgraded shares of Castle Biosciences from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, September 9th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Castle Biosciences presently has an average rating of "Moderate Buy" and an average target price of $37.00.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in Castle Biosciences by 2,070.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 217,794 shares of the company's stock valued at $4,360,000 after buying an additional 207,761 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Castle Biosciences in the 4th quarter worth approximately $230,000. Deutsche Bank AG boosted its position in Castle Biosciences by 12.5% during the fourth quarter. Deutsche Bank AG now owns 67,667 shares of the company's stock worth $1,803,000 after purchasing an additional 7,495 shares during the period. Man Group plc bought a new position in shares of Castle Biosciences in the fourth quarter valued at approximately $354,000. Finally, Cubist Systematic Strategies LLC grew its stake in Castle Biosciences by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 237,698 shares of the company's stock valued at $4,759,000 after buying an additional 60,161 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.